Latest Voices from Friends of MPPMPP licensing helps tackle antimicrobial resistanceAs we celebrate World AMR Awareness Week (WAAW), enabling access to new treatments can contribute to overcoming resistance to older treatments. For example, in 2013 MPP’s licences on second-line treatments such as atazanavir contributed to facilitating access to second line treatments that enabled people with resistance to first-line treatment to transition to a WHO recommended […]
20 November 2023
“The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19.”
Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
“As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation.”
Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
“Happy Anniversary! Developing better medicines for children is a very complex but rewarding task for our scientists in pharmaceutical development. Seeing new age-appropriate formulations reaching children WORLDWIDE thanks to the work of MPP is just wonderful! Please keep up the good work!”
Daniel Schaufelberger PhD, Janssen/J&J (retired), independent consultant and adj. assist. Professor at Johns Hopkins University
“The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives.”
Marisol Touraine, Chair of the Executive Board of Unitaid
“Heartiest congratulations on your 10th anniversary!! We have greatly benefitted from cooperation with MPP through the years. Your unflinching and transparent guidance and advise has added to our product portfolio in the HIV segment.
Thanks once again and wishing you many more successful years!!”
MANGALAM DRUGS & ORGANICS LTD
“You’ve taken Advocacy to another level. Advocacy per excellence! Kudos and keep up the good work. The future is bright.”
We would love to hear your comments on the mission and work of MPP!